Can individuals with Osteogenesis Imperfecta (OI) take statins (HMG-CoA reductase inhibitors)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Individuals with Osteogenesis Imperfecta (OI) can generally take statins, but caution is advised due to potential musculoskeletal side effects. Statins like atorvastatin, simvastatin, and rosuvastatin are primarily used to lower cholesterol and don't directly interfere with the collagen defects that cause OI 1. However, since some statins have been associated with musculoskeletal side effects such as myalgia (muscle pain) and rarely rhabdomyolysis (severe muscle breakdown), patients with OI should be monitored more carefully when starting these medications.

Key Considerations

  • People with OI already have fragile bones and sometimes muscle weakness, so any medication that could potentially affect the musculoskeletal system requires special consideration.
  • If a statin is needed for cardiovascular risk reduction, starting with a lower dose and gradually increasing while monitoring for side effects is recommended.
  • Hydrophilic statins like rosuvastatin or pravastatin may be preferred as they generally have fewer muscle-related side effects, as suggested by studies on statins and osteoporosis 2, 3.
  • Regular follow-up with both the prescribing physician and the specialist managing the OI is important to ensure the medication is well-tolerated and not exacerbating any OI-related symptoms.

Management Approach

  • The management of OI in adults involves a multidisciplinary approach, including periodic evaluations of other manifestations of OI, such as hearing loss, respiratory impairments, ocular and dental abnormalities, and cardiovascular disease 4.
  • While there is no consensus on how cardiovascular disease in OI should be assessed or managed, a recent study provides clinical guidance and recommendations for the care of adults with OI 1.
  • The use of statins in patients with OI should be individualized, taking into account the potential benefits and risks, and monitored closely for any adverse effects.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.